Intuitive Surgical, Inc. $ISRG Shares Bought by Gradient Investments LLC

Key Points

• Gradient Investments increased its Intuitive Surgical stake by 5.5% in the third quarter, bringing its holdings to 50,280 shares valued at approximately $20.45 million. Institutional investors collectively own 83.64% of the company.
• Analysts remain broadly positive on ISRG, with a consensus “Moderate Buy” rating and an average price target of $502.53; recent upgrades include Oppenheimer and BNP Paribas Exane.
• Intuitive Surgical reported quarterly revenue of $2.89 billion and EPS of $2.80, beating estimates, while revenue rose 18.4% year over year. Risks include premium valuation, increasing competition and upcoming earnings expectations.

Gradient Investments LLC lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 5.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 50,280 shares of the medical equipment provider's stock after acquiring an additional 2,640 shares during the quarter. Gradient Investments LLC's holdings in Intuitive Surgical were worth $20,445,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. North Point Portfolio Managers Corp OH acquired a new stake in Intuitive Surgical during the third quarter worth approximately $27,000. Main Street Group LTD acquired a new stake in shares of Intuitive Surgical during the first quarter worth $30,000. Compass Financial Management LLC bought a new stake in shares of Intuitive Surgical in the second quarter valued at about $30,000. Vermillion Wealth Management Inc. raised its stake in Intuitive Surgical by 58.1% in the 1st quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 25 shares in the last quarter. Finally, Motiv8 Investments LLC bought a new stake in Intuitive Surgical in the 4th quarter valued at about $34,000. Institutional investors own 83.64% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on ISRG shares. Piper Sandler reaffirmed an "overweight" rating on shares of Intuitive Surgical in a report on Friday, August 21st. BMO Capital Markets restated an "outperform" rating on shares of Intuitive Surgical in a research report on Monday, July 20th. KeyCorp restated an "overweight" rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. BNP Paribas Exane upgraded Intuitive Surgical to an "outperform" rating in a research note on Tuesday, July 28th. Finally, Oppenheimer upgraded Intuitive Surgical from a "market perform" rating to an "outperform" rating and set a $500.00 price target on the stock in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $502.53.

Insider Activity

In other Intuitive Surgical news, Director Gary Guthart sold 10,000 shares of the company's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total value of $4,000,000.00. Following the sale, the director owned 1,245,679 shares in the company, valued at approximately $498,271,600. The trade was a 0.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 400 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the sale, the director owned 251 shares in the company, valued at $95,129. This trade represents a 61.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 12,370 shares of company stock worth $4,891,989. 0.60% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Up 0.1%

Shares of NASDAQ ISRG traded up $0.28 during midday trading on Thursday, reaching $414.80. 866,754 shares of the company were exchanged, compared to its average volume of 2,414,874. The stock's 50-day moving average price is $383.70 and its 200-day moving average price is $411.61. The stock has a market cap of $146.54 billion, a P/E ratio of 47.55, a PEG ratio of 3.05 and a beta of 1.46. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The company had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same quarter last year, the business posted $1.81 EPS. Intuitive Surgical's revenue for the quarter was up 18.4% on a year-over-year basis. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Barclays initiated coverage with an Overweight rating and later upgraded ISRG to Strong Buy. The firm’s bullish stance provides a positive catalyst and suggests confidence in Intuitive Surgical’s market position despite a softer medical-device environment. Barclays initiates coverage of Intuitive Surgical at Overweight Intuitive Surgical upgraded at Barclays
• Positive Sentiment: Wall Street analysts remain optimistic. Coverage highlights expectations for year-over-year revenue and earnings growth, while Citi has also issued a Buy rating. Such recommendations may encourage buying interest in the shares. Wall Street analysts look optimistic on Intuitive Surgical Intuitive Surgical gets a Buy from Citi
• Positive Sentiment: The da Vinci Single-Port platform is gaining momentum. Rising procedure volumes, utilization, placements, expanding indications and international adoption could create another significant recurring-revenue growth engine for Intuitive Surgical. Can ISRG’s Single-Port Platform Become the Next Billion-Dollar Franchise?
• Neutral Sentiment: Investors are focused on the upcoming October 20 earnings report. Results and management’s outlook will be important in determining whether the recent analyst optimism and expected growth are justified. Barclays’ bullish initiation amid rising rivalry
• Negative Sentiment: Competition and valuation remain risks. Commentary points to growing rivalry, particularly from Johnson & Johnson, while ISRG’s premium valuation could limit upside or increase sensitivity to an earnings miss. Intuitive Surgical and JNJ give Jim Cramer more than valuation to consider

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company's products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.